peptideInjectable
PT-141
Also known as: Bremelanotide, Vyleesi
Half-life
2 h
Typical timing
any
Food rule
either
Default unit
mg
Overview
PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide melanocortin receptor agonist. It is structurally derived from alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike some other compounds aimed at sexual health, PT-141 acts centrally on the brain rather than on the vascular system. It was initially investigated for its tanning properties due to its relation to alpha-MSH, which plays a role in melanogenesis. However, its significant effect on sexual arousal was discovered serendipitously during clinical trials. Bremelanotide was subsequently developed specifically for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Its administration is typically via subcutaneous injection or as a nasal spray, though the injectable form is the version approved for therapeutic use in some regions. The compound has a relatively short half-life of approximately 2 hours in the human body. As a prescription medication, its use is guided by a licensed clinician.
Deep dive
Tap a section to expand.
Known interactions
- Category rule: peptide × hormoneNote
Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.
Track bloodwork with a provider; don't assume combinations are neutral.
Frequently asked
Sources referenced
* Food and Drug Administration (FDA) Labeling Information
* MedlinePlus
* PubChem
* Clinical trial publications cited by FDA
* Examine.com
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the peptide category or studied for the same goals.
Track PT-141 in Stackwise
Add it to your stack. We'll schedule doses, check interactions against everything else you take, and remind you at the right time.
Sign up free →